-
plasma nesfatin-1 levels were found to be high in patients with coronary artery disease (CAD) and were associated with CAD independent of atherosclerotic risk factors
-
nesfatin-1 is potential novel biomarker for the prediction and early diagnosis of Gestational Diabetes Mellitus.
-
Nesfatin-1 levels are inversely associated with severity of carotid artery stenosis and plaque morphology.
-
Authors demonstrated that KLF4 was induced by ER stress in melanoma cells, and increased KLF4 inhibited cell apoptosis and promoted cell metastasis. Further mechanistic studies revealed that KLF4 directly bound to the promoter of NUCB2, facilitating its transcription.
-
Nesfatin-1 is involved in cardiovascular regulation, stress-related responses.
-
NUCB2 played an important role in bladder cancer and could be considered a potent prognostic factor
-
Serum nesfatin-1 levels were significantly lower in major depressive disorder patients with suicidal ideation compared to healthy volunteers.
-
Study data identified nesfatin-1 as a key modulator in hypertension and vascular remodeling by facilitating vascular smooth muscle cells phenotypic switching and proliferation.
-
intensity of exercise may have an important role in changes of nesfatin-1, leptin, FFA, and epinephrine concentrations even though this was not the case for IL-6 and insulin resistance
-
Patients with schizophrenia had significantly higher serum nesfatin-1 levels compared to healthy controls.
-
This study finds that soccer matches performed different workout times have strong stimulatory effects on irisin levels in all subjects but nesfatin-1 response varied among the subjects and it did not change significantly in afternoon match.
-
serum nesfatin-1 concentrations were inversely correlated with atrial fibrillation development.
-
In all trimesters of human pregnancy, NUCB2/nesfatin-1 was highly expressed in syncytiotrophoblast. In addition, there was a significant increase in NUCB2 expression in human primary trophoblast cells induced to syncytialise.
-
Data suggest that circulating nesfatin-1 levels are up-regulated in patients newly diagnosed with type 2 diabetes; non-newly diagnosed patients treated with antidiabetic medications exhibit lower circulating nesfatin-1 levels. [META-ANALYSIS, REVIEW]
-
Data suggest that levels of nesfatin-1 in maternal serum and cord blood are up-regulated in women with gestational diabetes (GD) as compared to control pregnant women; nesfatin-1 also appears to be up-regulated in subcutaneous abdominal adipose tissue in GD. This study was conducted in China in women of the Han ethnicity.
-
expressions of p-Akt/Akt and p-GSK-3beta/GSK-3beta in the myocardium of MI group rats were significantly increased by nesfatin-1 administration, suggesting that nesfatin-1, which appears to possess anti-apoptotic and anti-inflammatory properties, may confer protection against ISO-induced MI via an Akt/GSK-3beta-dependent mechanism.
-
Study demonstrated that high expression level of NUCB2 was significantly associated with poor clinical outcome of patient with non-metastatic clear cell renal cell carcinoma.
-
The multifunctional biological actions of nesfatin-1 propelled this peptide as a therapeutic target, and as a potential biomarker of diseases. However, a better and comprehensive understanding of tissue specific effects of nesfatin-1 is critical prior to exploring its possible use in the detection and treatment of diseases.
-
Data indicate that nesfatin-1/NUCB-2 enhanced migration, invasion and epithelial-mesenchymal transition (EMT) in colon cancer cells through LKB1/AMPK/TORC1/ZEB1 pathways in vitro and in vivo.
-
Nesfatin-1 levels decrease following biliopancreatic diversion with duodenal switch-induced weight loss and are significantly associated with parameters of metabolic health.